
Navigating The Treatment of Schizophrenia Using LAIs In The Time of COVID-19
The rapid onset of COVID-19 in the United States, combined with the dismantling of the spring 2020 medical conference infrastructure and widespread travel bans and social distancing has created a synchronous need in all clinical arenas to manage patients with pre-existing conditions, such as schizophrenia, who require management with LAIs. Join our expert faculty for this on-demand online activity, focusing on their expert insights into guiding patients, caregivers, and clinicians on using LAIs during the global health pandemic of COVID-19.
This activity is supported by an educational grant from Alkermes.
This activity has been developed and accredited by Creative Educational Concepts, Inc. in partnership with the College of Psychiatric and Neurologic Pharmacists (CPNP).
Target Audience
Physicians, pharmacists, nurse practitioners, and nurses treating patients with LAIs in the time of COVID-19.
Learning Objectives
- Outline current and emerging pharmacotherapy treatment options for schizophrenia, including mechanisms of action and formulations.
- Identify gaps in the current schizophrenia treatment paradigm, given the challenges of COVID-19, and give suggestions for increasing intervals of dosing and how to handle missed injections.
Additional Information
Christoph U. Correll, MD (Activity Chair)
Professor of Psychiatry
Donald and Barbara Zucker School of Medicine
Hofstra/Northwell
New York, New York
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC
Psychiatric Associates of Central Texas
Affiliate faculty, University of Texas at Austin School of Nursing
Austin, Texas
Leigh Anne Nelson, PharmD, BCPP
Associate Professor
University of Missouri Kansas City School of Pharmacy
Kansas City, Missouri
Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Planners
Christoph U. Correll, MD–has disclosed that he is a consultant for Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He also receives grant/research from Janssen and Takeda.
Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Steve Stoner, PharmD, BCPP–has disclosed that he is on the speakers’ bureau for Neurocrine.
Faculty
Christoph U. Correll, MD–has disclosed that he is a consultant for Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He also receives grant/research from Janssen and Takeda.
Stella J. Logan APRN, PMHCNS-BC, PMHNP-BC–has no relevant financial relationships to disclose in relation to the content of this activity.
Leigh Anne Nelson, PharmD, BCPP–has disclosed that she receives grant/research support from Alkermes, Auspex, Boehringer-Ingelheim, and Neurocrine.
Content Reviewers
Andrew Cutler, MD-has disclosed that he is a consultant for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion; he receives grant/research support from Alkermes IntraCellular Therapies Janssen, Lundbeck, Otsuka, and Sunovion. He also is a member of the speakers’ bureau for Alkermes, IntraCellular Therapies, Janssen, Lundbeck, Otsuka, and Sunovion.
Deanna Kelly, PharmD, BCPP–has disclosed that she is consultant for Alkermes.
Amanda Simonton, ARNP–has disclosed that she is on a Medscape Education Steering Committee that is supported by grant money from Alkermes.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME): CEC designates this live educational activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners (AANP): This activity is approved for 0.5 contact hour(s) of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 20084420. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Nursing (ANCC): This activity is designated for 0.50 contact hour.
Upon completion of a CE Request Form, statements of credit for physicians and nurses will be issued automatically.
Available Credit
- 0.50 AANP Contact Hours
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 Participation